Who we are?
Harry Lander
CEO
Ph.D., MBA
Has over 25 years of professional scientific, business and financial management experience related to biomedical research. Dr. Lander has extensive relationships with large and small biotechnology / pharmaceutical companies and entities that NeuroProtect expects to leverage for company growth. Dr. Lander is currently President and Chief Scientific Officer of Regen BioPharma, Inc. a publicly traded biotechnology company. Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar) and Assistant Provost for Weill Cornell Medical College (Cornell University).

Guriq Basi
Head of Pre-Clinical Development
Ph.D
Was former chief scientific officer of Elan Pharmaceuticals (antibody humanization, protein engineering, and protein expression; antibody drugs in CNS indications, review and approval of IND sections) and former SVP of Adverum Biotechnology (Gene therapy of Ocular indications & rare disease), CSO of Circuit Therapeutics (Optogenetics for CNS disease)

Michael Agadjanyan
Chief Scientific Officer
Ph.D., D.Sc.
Vice-President, Head of Department of Molecular Immunology, Professor, Institute for Molecular Medicine, Huntington Beach, CA and Adjunct Professor of the Institute for Memory Impairments and Neurological Disorders at University of California, Irvine. Over 30 years of experience in immunology, molecular biology and recognized as a national leader in the development of vaccines targeting brain disorders with over 125 publications in peer-reviewed journals. He is a co-inventor of the technology.
James Callaway
Senior Consultant
Ph.D
Has over 30 years of experience in the biopharmaceutical industry having led efforts to transition numerous drugs into early stage clinical trials as well as U.S. and EU drug approvals of biotherapeutics. Former Senior Vice President Alzheimer Program Executive for the ground-breaking Alzheimer's Disease immunotherapy program at Elan from 1999 when we initiated our active vaccine program with AN-1792 through 2008 when Phase II results with bapineuzumab were reported. Dr. Callaway led large teams through biological development all the way to product formulation. He was also President and CEO of Cebix, Inc. and ArmaGen, Inc.

Roman Knyazev
Chief Financial Officer
MBA
Experienced investment director of one of the biggest European investment funds with a demonstrated history of working in the venture capital and private equity industry. Has strong Life Science specialization and a track record of 7 launched projects. On the Boards of 5 biotech companies specializing in discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. Graduate of the Kauffman Fellowship program in USA.

Anahit Gohichyan
Head of Basic Science
Ph.D.
Professor Institute for Molecular Medicine, Huntington Beach, CA; International expert in immunotherapy of neurodegenerative disorders, antibody-mediated clearance of Aß, tau, α-synuclein. Co-inventor of the technology

David Cribbs
Scientific Advisor
Ph.D.
Professor in Residence, Neurology, UCI School of Medicine and Associate Director of the MIND Institute at University of California, Irvine is an expert on age-related factors responsible for the initiation and the progression of Alzheimer's Disease, antibody-mediated clearance of Aß, identifying risk factors associated with immunotherapy in elderly Alzheimer's Disease patients. He has been appointed to the Department of Veterans Affairs Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services. Dr. Cribbs is longtime collaborator of Dr. Agadjanyan and he is directly involved in their vaccine projects.

Lon Schneider
Scientific Advisor
M.D.
Director, USC Alzheimer's Disease Research and Clinical Center and Director, pharmacology program, USC NIH Alzheimer's Disease Research Center and Professor of psychiatry and the behavioral sciences and neurology, Keck School of Medicine of USC and Professor of gerontology, USC Davis School of Gerontology. An international leader in age-related neurological and neuropsychological disorders and clinical trials.

Hongang Bi
Commercial Advisor
Ph.D.
Corporate Vice President and General Manager, China for Covance Pharmaceutical, Shanghai, China. Covance is one of the largest contract research organizations in the world specializing in clinical trials.